Cambridge Cognition's total revenue increased by 11.3% to £3.26m in the six months to the end of June.
The loss before interest, tax, depreciation and amortisation narrowed to £0.11m from £0.26m loss and pre-tax losses reduced to £0.15m (H1 2015: £0.28m loss).
Chief executive Steven Powell said: "The results from the first half of the year reflect the significant advances that have been made in marketing of our core products and technology developments that have resulted in the launch of our online and wearable platforms.
"Our products and technologies are now aligned with all stages of our customers' drug development cycle and the commercial focus is now set to maximise the opportunities presented by existing sales channels."
At 9:15am: (LON:COG) Cambridge Cognition Holdings share price was -3p at 73.5p